Table 2 Patient distribution according to initial OAD prescription and by year of first OAD administration
Year of first OAD administration | Total | |||||
|---|---|---|---|---|---|---|
2006 | 2007 | 2008 | 2009 | 2010 | ||
Number of patients | 11,564 | 12,277 | 12,419 | 13,251 | 13,549 | 63,060 |
Mono: metformin | 84.4 | 87.1 | 88.1 | 89.3 | 90.7 | 88.1 |
Mono: gliclazide | 10.3 | 9.0 | 8.5 | 7.6 | 5.9 | 8.1 |
Comb: metformin and gliclazide | 1.2 | 1.2 | 1.7 | 1.5 | 1.7 | 1.5 |
Mono: glimepiride | 1.1 | 0.8 | 0.6 | 0.5 | 0.4 | 0.7 |
Mono: other | 1.3 | 0.7 | 0.4 | 0.3 | 0.6 | 0.6 |
Mono: glipizide | 0.5 | 0.4 | 0.3 | 0.3 | 0.1 | 0.3 |
Comb: other | 0.6 | 0.3 | 0.1 | 0.1 | 0.2 | 0.3 |
Mono: pioglitazone | 0.4 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
Comb: metformin and other | 0.2 | 0.2 | 0.1 | 0.2 | 0.2 | 0.2 |
Comb: metformin and glimepiride | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |